Loading...
Market
In how many EU countries will WINREVAIR™ be reimbursed by national health insurance by December 31, 2024?
2
Resolution / Starting Odds
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Official announcements from national health insurance bodies or Merck's press releases
Story
Merck's WINREVAIR™ Gains EU Approval for PAH Treatment
Aug 26, 2024, 06:41 AM
Merck has received approval from the European Commission for WINREVAIR™ (sotatercept) in combination with other therapies for the treatment of pulmonary arterial hypertension (PAH) in adult patients with functional class II-III. This approval marks a significant advancement in the treatment options available for PAH, a condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure if untreated. The approval of WINREVAIR™ is expected to enhance the therapeutic landscape for PAH patients in Europe.
View original story
Similar markets
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16+ countries • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
0-5 new countries • 25%
6-10 new countries • 25%
11-15 new countries • 25%
More than 15 new countries • 25%
More than 20 countries • 25%
15-20 countries • 25%
10-14 countries • 25%
Less than 10 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Germany • 25%
France • 25%
Italy • 25%
Spain • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%